Literature DB >> 28676025

Nonalcoholic Fatty Liver Disease vs. Nonalcoholic Steatohepatitis: Pathological and Clinical Implications.

Chrysoula Boutari1, Petros Lefkos2, Vasilios G Athyros1, Asterios Karagiannis1, Konstantinos Tziomalos3.   

Abstract

The implications and prognosis of nonalcoholic fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH) are substantially different. The aim of the present review is to describe and compare the pathological and clinical implications of these two conditions. Patients with NASH have a higher risk of progressing to cirrhosis than patients with NAFL but without steatohepatitis, who tend to have a non-progressive disease and only a minority progresses to NASH. Patients with NASH also are at greater risk to develop hepatocellular cancer (HCC) and NASH is the third commonest cause of HCC. In contrast, only few cases of HCC have been reported in patients with isolated NAFL. Given that nonalcoholic fatty liver disease is the hepatic manifestation of metabolic syndrome, it is also strongly related to cardiovascular disease (CVD). Again, it appears that patients with NASH have higher cardiovascular risk than patients with NAFL. Finally, all-cause mortality is also higher in patients with NASH than in patients with NAFL; mortality rates in the latter patients do not differ from the general population. In conclusion, NAFL and NASH have different prognosis and therefore it is imperative to develop accurate, noninvasive methods that will identify the presence of steatohepatitis in this population. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Nonalcoholic fatty liver; all-causezzm321990mortality.; cardiovascular risk; cirrhosis; hepatocellular cancer; nonalcoholic steatohepatitis

Mesh:

Year:  2018        PMID: 28676025     DOI: 10.2174/1570161115666170621075157

Source DB:  PubMed          Journal:  Curr Vasc Pharmacol        ISSN: 1570-1611            Impact factor:   2.719


  5 in total

Review 1.  Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH).

Authors:  Xiaohan Xu; Kyle L Poulsen; Lijuan Wu; Shan Liu; Tatsunori Miyata; Qiaoling Song; Qingda Wei; Chenyang Zhao; Chunhua Lin; Jinbo Yang
Journal:  Signal Transduct Target Ther       Date:  2022-08-13

Review 2.  Overview of Non-Alcoholic Fatty Liver Disease (NAFLD) and the Role of Sugary Food Consumption and Other Dietary Components in Its Development.

Authors:  Pau Vancells Lujan; Esther Viñas Esmel; Emilio Sacanella Meseguer
Journal:  Nutrients       Date:  2021-04-24       Impact factor: 5.717

3.  Deletion of KLF10 Leads to Stress-Induced Liver Fibrosis upon High Sucrose Feeding.

Authors:  Junghoon Lee; Ah-Reum Oh; Hui-Young Lee; Young-Ah Moon; Ho-Jae Lee; Ji-Young Cha
Journal:  Int J Mol Sci       Date:  2020-12-30       Impact factor: 5.923

4.  Association between Subclinical Low Serum 25(OH)D in Donors and Fatty Liver Disease in Recipients after Living Donor Liver Transplantation.

Authors:  King-Wah Chiu; Toshiaki Nakano; Tsung-Hui Hu; Kuang-Den Chen; Li-Wen Hsu; Hock-Liew Eng; Yu-Fan Cheng; Shigeru Goto; Chao-Long Chen
Journal:  Biomed Res Int       Date:  2018-03-19       Impact factor: 3.411

5.  Superficial vs Deep Subcutaneous Adipose Tissue: Sex-Specific Associations With Hepatic Steatosis and Metabolic Traits.

Authors:  Tessa Brand; Inge Christina Lamberta van den Munckhof; Marinette van der Graaf; Kiki Schraa; Helena Maria Dekker; Leonardus Antonius Bernardus Joosten; Mihai Gheorghe Netea; Niels Peter Riksen; Jacqueline de Graaf; Joseph Henricus Wilhelmus Rutten
Journal:  J Clin Endocrinol Metab       Date:  2021-09-27       Impact factor: 5.958

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.